Introduction
Lysergic acid diethylamide (LSD) is a highly potent hallucinogen that induces mental disorientation characterized by impairment of behavioral control, altered sensory perception, hallucinations, and difficulty in thinking and concentration. In the military, a major concern of LSD abuse is the long duration of action (up to 12 h) (1) and the potential to leave users unable to reliably perform tasks requiring short-term memory and concentration. This poses a serious problem for service members working in situations where safety is dependent on the reliable functioning of others. Consistent with these concerns, the United States Navy Drug Screening Laboratories have been ' Disclaimer: The opinions contained in the publication are not to be construed as official or as reflecting the views of the Oepanment of Defense or the Department of the Navy, t Author to whom correspondence should be addressed. E-mail: kklene@nhgl,mednavy.miL testing for LSD by gas chromatography-mass spectrometry (GC-MS) since 1987 (2) . However, the combined effects of the low doses consumed (40-120 IJg) and extensive rapid metabolism (i.e., less than 1% excreted unchanged in urine) contribute to an extremely short window of detection (12-22 h) when using LSD as the target analyte (3--6) . Recently, several analytical systems, including liquid chromatography-ion trap mass spectrometry (LC-MS-MS) (7, 8) , liquid chromatography-mass spectrometry (LC-MS) (8, 9) , and gas chromatography-tandem mass spectrometry (GC-MS-MS) (10, 11) that target a prevalent human LSD metabolite, 2-oxo-3-hydroxy lysergic acid diethylamide (O-H-LSD) (12) , have been reported.
The purpose of the current study was to develop a rapid and efficient single-step solid-phase extraction procedure for the subsequent LC-MS analysis of O-H-LSD in human urine samples. The developed LC-MS method was optimized to identify and quantitate O-H-LSD using Department of Defense (DoD) forensic analysis criteria. The method was validated regarding analyte recovery, accuracy, precision, linearity, and specificity. The current O-H-LSD confirmation method used at this laboratory requires a multistep extraction procedure (8) . The extraction step requires approximately 4 to 5 h for a set of 20 specimens and produces a large stream of chlorinated solvent waste.
Methods

Materials
Extractions utilize a Speedisk 48 positive-pressure extraction manifold (J.T. Baker, Phillipsburg, N J) equipped with polymer-based anion exchange extraction columns (Cerex Polycrom CLIN II columns, 50 rng, 5-mL capacity, SPEware, San Pedro, CA). Reagent-grade methanol, ethyl acetate, hydrochloric acid, ammonium hydroxide, potassium carbonate, potassium bicarbonate, sodium phosphate, high-performance liquid chromatography (HPLC)-grade acetonitrile, and amino-nium acetate were obtained from Fisher Scientific (Pittsburgh, PA). Control materials were prepared in certified drug-free urine from Roche Diagnostics Inc. (Nutley, NJ) using O-H-LSD purchased from Cerilliant Inc. (Austin, TX). The internal standard, 2-oxo-3-hydroxy lysergic acid methyl propylamide (O-H-LAMPA), was purchased from Cerilliant Inc. Working solutions of the internal standard were prepared in methanol. A TurboVap TM LV Evaporator sample concentrator from Zymark Corp. (Hopkinton, MA) was used to evaporate solvents.
Extraction
The solid-phase positive-pressure manifold (PPM) extraction used a 5-mL aliquot of urine. To each tube, 100 mL (200 ng/mL) of O-H-LAMPA (internal standard) and 2 mL of 100mM phosphate buffer (pH 6.0) were added. Samples were mixed and then centrifuged for 2 rain at 2000 rpm. Samples were then transferred onto the columns and pushed through with positive pressure of 1 psi. Next, 1 rnL of potassium carbonate/ potassium bicarbonate buffer (pH 9.0) was applied to the columns, followed by 2 mL 0.1M HCl. Positive pressure (3-5 psi) was applied after each reagent addition. The columns were washed with 1 mL methanol and 3 mL ethyl acetate. The target compounds were eluted by gravity with the addition of 4 mL of ethyl acetate containing 4% ammonium hydroxide to the columns. The tubes were dried in a Zymark TurboVap heated to 55~ Samples were reconstituted for injection with 200 I~L of 0.01M ammonium acetate (pH 8.0)/acetonitrile (80:20).
Instrumentation
All analyses were performed using an Agilent 1100 LC-MS as described previously (8) , with the following exception to the HPLC portion of the method: the initial ratio of buffer to acetonitrile was 79:21 using a constant flow rate of 0.8 mL/min. This initial ratio was held for 2 rain and was changed to 63:37 over the course of the 9.0-rain run. The column was re-equilibrated for 5 min after the completion of the run. The total run time was 14 min. Additionally, the injection volume was reduced from 90 to 60 IJL.
The MS was operated in the selective ion monitoring mode (SIM) with the following ions being monitored: the parent ion, single-point calibration against the 1000-pg/mL standard. Identification of O-H-LSD was considered acceptable if the specimens and controls exhibited retention times within • 1% and identity ion abundance ratios within • 20% of the calibration standard. Additionally, all O-H-LSD controls within each analytical set were required to quantitate within • 20% of the expected theoretical concentration.
Results and Discussion
tinearity and recovery
The linearity of the method was determined by analyzing increasing concentrations of O-H-LSD until one or more of the qualifying ratios failed or the determined concentration fell outside • 20% of the expected concentration. The assay was linear [r 2 of 0.999 (F = 19554.31, df = 23)] over concentrations ranging from 250 to 30,000 pg/rnL. The mean of the linearity standards (n = 4) was within 13% of the expected concentrations, and the coefficient of variation (%CV) was less than 7 (Table I ).
The limits of detection (LOD) and quantitation (LOQ) for the method were determined by analyzing decreasing concentrations of O-H-LSD. Four replicates each of 250-, 500-, and 1000-pg/mL standards were extracted and analyzed by LC-MS as described. The LOD was defined as the lowest concentration of analyte detected with all mass ratios within • 20% of the calibrator. The LOQ was defined as the lowest concentration detected with all mass ratios within • 20% of the calibrator and 230  243  238  2  500  540  591  606  3  1000  1200  1236  1185  4  10,000  9530  11,530  11,419  5  200  220  255  263  6  500  620  610  556  7  1000  t240  1204  1165  8  10,000  8950  11,162  11,219  9  200  230  226  254  10  500  650  610  595  11  1000  1150  1279  1257  12  10,000  9330  11,890  11,472  13  200  240  258  290  14  500  460  612  634  15  1000  1120  1264  1231  16  10,000  9290  11,864  11,017  17  200  240  253  277  18  500  510  621  620  19  1000  1130  1231  1279  20  10,000  9110 the concentration within f 20% of the expected target value. The resulting LOD and LOQ of the method was 250 pg/mL (Table I) , which is less than the reported value of 400 pg/mL for the previously reported method (8) . Analyte recovery was calculated by analyzing two sets of five certified drug-free urine samples spiked with O-H-LSD at 1000 pg/mL. In the first set the internal standard (2000 pg/mL, 2-oxo-3-hydroxy LAMPA) was added at the beginning of the procedure and extracted as described. In the second set, the internal standard was added after elution of the O-H-LSD was complete. The percent recovery through the SPE column, calculated by dividing the average of the O-H-LSD/internal standard area for the first set by the average of the O-H-LSD/ internal standard area for the second set, was 92%. When compared with the current multistep extraction procedure, the solid-phase technology produced a 45% increase in extraction efficiency, a 38% decrease in the assays LOD and LOQ and a 33% reduction in injection volume. These efficiencies were achieved without compromising chromatographic peak symmetry, resolution, and signal-to-noise (S/N) ratios.
S/N calculations were performed automatically using Target data analysis software from ThermoLab Systems (Beverly, MA). Instrument noise was initially derived using the instruments programmed integration parameters, and the S/N values were calculated by taking the ratio of the root mean square (RMS) of the peak at the retention time of O-H-LSD and dividing by the RMS of a portion of the baseline. Between-run S/N ratios of an open O-H-LSD control containing 500 pg/mL O-H-LSD over the course of seven separate batches produced an average S/N ratio of 130.13.
Peak symmetry was calculated automatically using Target data analysis software. The software determines the height of a vertical line drawn from the apex of the peak of interest to the baseline. At 10% of the peak height, the ratio of the length of a parallel line drawn from the leading edge of the peak to centerline is divided by the length of the same line from centerline to the trailing edge of the peak. Between-run symmetry calculations of the 500-pg/mL O-H-LSD open control over the course of seven separate batches produced a mean value of 1.41 (range 1.18-1.73).
The within-run precision was determined by analyzing 10 replicates of certified drug-free urine spiked with O-H-LSD at the LC-MS cutoff concentration (1000 pg/mL). The precision samples yielded an average response of 997 pg/mL and a %CV of 2.0. Between-run precision of a 500-pg/mL control over the course of 12 separate batches produced a mean value of 515 pg/mL with a %CV of 3.4. A certification set of 20 O-H-LSD samples prepared by an independent laboratory was analyzed using the described method and the current LC-MS procedure. The set included five replicates each of O-H-LSD standards prepared at 200, 500, 1000, and 10,000 pg/mL (Table II) . The correlation between the current method and the new reported method was excellent (r 2 = 0.999). By a one-way, fixed-effect analysis of variance comparing the three laboratory analyses of the samples (in Table II) , the results were not significantly different between laboratories at the cr = 0.05 level (F = 0.1163,p = 0.8903).
LC-MS analysis of archived samples
The method was also validated using nine human urine specimens randomly that had been collected from military service members and were authorized for destruction. These samples, previously found to contain LSD at concentrations ranging from 216 to 3204 pg/mL by GC-MS (9), were removed after 1-3 years of frozen storage. The samples were thawed, extracted, and reanalyzed for LSD and O-H-LSD using the present LC-MS procedure. Eight of the nine specimens produced a mean O-H-LSD concentration of 18,862 pg/mL, ranging from 332 to 37,338 pg/mL (Table III) . The presence of LSD was monitored using the rn/z 324 for LSD and LAMPA (internal standard) for the purpose of comparing relative concentrations of O-H-LSD and LSD in the samples. The mean O-H-LSD concentration was approximately 25 times higher than the LSD concentration. This data is in agreement with previously published data that demonstrate O-H-LSD is present in significantly higher concentrations than LSD in human urine samples (7, 8) .
The stability of O-H-LSD in a previous study was found to be similar to that of LSD; O-H-LSD samples stored for 60 days at -20~ showed no significant loss of O-H-LSD at pHs ranging from 4.6 to 8.4 (13) . A set of samples prepared as part of the original study was stored for a one-year period at -20~ and at the same pH ranges. Analysis of these samples by the same methods used for the original stability study (13) showed no loss of O-H-LSD, demonstrating its long-term stability (Table  IV) . The inability to detect O-H-LSD in the one discrepant sample (sample #6 on Table III) may be related to sample degradation because the specimen was stored for 3 years at-20~ and the pH of the sample was 9.0 (13). 
Interference study
The specificity/interference of the method was investigated by challenging the assay with compounds that are commonly used within the testing population such as common over-the-counter (OTC) products, prescription drugs, and some of their metabolites, and other illicit compounds. These compounds were a combination of commercially available mixtures and in-house prepared single-and multi-constituent interference standards. The compounds were analyzed in the presence of O-H-LSD at a concentration of 1000 pg/mL and were evaluated for their potential of coeluting with and/or possessing ions common to O-H-LSD and the internal standard (O-H-LAMPA). The corn- Table V pounds ranged in concentration from 0.2 to 2.5 mg/L and were representative of therapeutic levels or for the illicit drugs were above the Department of Health and Human Services or the DoD GC-MS cutoff concentration (Table V) . A solvent blank was placed between each interference standard to guard against carryover. All of the 78 compounds were chromatographically separated from O-H-LSD and produced no interference with respect to the correct identification or quantitation of O-H-LSD. Notably, acebutolol, which has previously been reported to interfere with the analysis of O-H-LSD (13), was chromatographically separated from O-H-LSD. The relative retention time of acebutoloi was 1.09 to that of O-H-LSD. The assay was also challenged as described with 15 compounds that have structural and chemical properties similar to O-H-LSD, specifically, compounds derived from naturally occurring ergot alkaloids that contain the backbone structure of lysergic acid and other LSD-related compounds (Table VI) . Ergot alkaloids as a group are used for the treatment of migraine and cluster headaches, postpartum hemorrhage, prolactinoma, prolactinaemiaoma, and for the management of dystonias associated with Parkinsonism. Ergonovine, also known as ergometrine, is also used for the prevention and treatment of postpartum hemorrhage and for the diagnosis and testing of variant angina and esophageal spasm (15).
Of the 15 compounds, only ergonovine was found to interfere with the analysis of O-H-LSD. When ergonovine was present in the absence of O-H-LSD, the ion ratios (338/356, 237/356) far exceeded the • 20% range as established by the calibrator and would not be falsely identified as O-H-LSD. When ergonovine was present in combination with O-H-LSD (1000 pg/mL) at concentrations lower than 10,000 pg/mL, no interference was noted with either O-H-LSD ion ratios or the appropriate quantitation of O-H-LSD.
The cross-reactivity of ergonovine with immunoassays designed to detect LSD has previously been reported (16) . The minimum concentration required to trigger a response that exceeds the assays LSD cutoff concentration (200 pg/mL) was 2000, 3000, and greater than 4000 ng/mL for the Diagnostics Products Corp. (DPC | RIA, Dade Behring EMIT | II, and Microgenics CEDIA | respectively. In contrast, O-H-LSD at 100 ng/mL produced positive responses in all three assays. The relative insensitivity of these assays to ergonovine and greater sensitivity to O-H-LSD alone would suggest the immunoas- 
Conclusions
The reported method for the quantitative determination of O-H-LSD in urine was precise, accurate, and reproducible. The solid-phase extraction procedure using the PPM was reliable, simple for technicians to perform, and eliminated time consuming liquid extraction clean-up steps, resulting in a twofold reduction in extraction time. Furthermore, the solid-phase extraction provided a twofold increase in extraction efficiency, resulting in a lower LOQ and a reduction in injection volume as compared with our current multistep extraction procedure. The method produced approximately 3 mL of organic solvent waste per sample and eliminated over 20 mL per sample of chlorinated solvents, as compared to the previously reported methodology. Overall, this solid-phase extraction PPM method with LC-MS analysis for the O-H-LSD metabolite meets forensic acceptance and efficiency criteria and is useful in highvolume drug-testing laboratory settings.
